Search

Your search keyword '"A. Muntañola"' showing total 1,160 results

Search Constraints

Start Over You searched for: Author "A. Muntañola" Remove constraint Author: "A. Muntañola"
1,160 results on '"A. Muntañola"'

Search Results

2. P1277: MUTATIONAL LANDSCAPE AND COPY NUMBER ALTERATIONS IN TESTICULAR LARGE B-CELL LYMPHOMA

3. Testicular large B‐cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL

5. New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group

7. Trends in hospitalisation for urinary tract infection in adults aged 18-65 by sex in Spain: 2000 to 2015.

10. Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting

12. Severity and organ distribution of graft‐versus‐host disease with post‐transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA‐matched or single‐allele mismatched stem cell transplantation

13. Testicular large B‐cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL.

15. Trends in hospitalisation for urinary tract infection in adults aged 18–65 by sex in Spain: 2000 to 2015

16. El futuro de la formación de los arquitectos y de las arquitectas tras cincuenta años de investigación

17. What is happening to modern architecture? = ¿Qué está sucediendo en la arquitectura moderna?

19. Leyendo a Rosario de Acuña en su centenario. Visiones finiseculares para nuestro milenio

21. RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group

22. New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group.

25. Party-appointed arbitrators in international commercial arbitration

26. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome

27. All-CLL: A Capture-based Next-generation Sequencing Panel for the Molecular Characterization of Chronic Lymphocytic Leukemia

28. Early progression in follicular lymphoma in the absence of histological transformation or high‐risk Follicular Lymphoma International Prognostic Index still has a favourable outcome

29. Novel therapies for the treatment of relapsed‐refractory aggressive B‐cell lymphoma increase survival. Analysis from the RELINF registry of the GELTAMO group

30. FACTORS INFLUENCING SURVIVAL AND PROLONGED VIRAL REPLICATION IN PATIENTS WITH LYMPHOMA AND COVID‐19: AN OBSERVATIONAL COHORT STUDY FROM GELTAMO SPANISH GROUP

32. El Col·legi de Metges, Barcelona, 1964-1968 : Robert Terradas i Via, un outsider absolutament innovador

33. Foreword

34. Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome

35. The interplay between architecture and education = El juego entre la arquitectura y la educación

36. Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group

37. Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

38. Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

43. Supplementary Table 1 from Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status

44. Data from Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status

45. Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial

47. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial

49. Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group

50. Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

Catalog

Books, media, physical & digital resources